<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of gynecomastia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of gynecomastia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of gynecomastia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Glenn D Braunstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley D Anawalt, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alvin M Matsumoto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 10, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gynecomastia, a benign proliferation of the glandular tissue of the male breast, is caused by an increase in the ratio of estrogen to androgen activity. It is categorized as physiologic (occurring normally during infancy, puberty, and older age) or pathologic (due to drugs or disorders such as androgen deficiency, testicular tumors, hyperthyroidism, and chronic kidney disease). In adult men seeking consultation for gynecomastia, approximately 40 percent of cases of gynecomastia are due to persistent pubertal gynecomastia or medications and 25 percent are idiopathic  (<a class="graphic graphic_table graphicRef53468" href="/z/d/graphic/53468.html" rel="external">table 1</a>) [<a href="#rid1">1</a>].</p><p>True gynecomastia should be differentiated from pseudogynecomastia (lipomastia), which refers to fat deposition without glandular proliferation. Gynecomastia must also be differentiated from breast carcinoma, which is far less common.</p><p>The management of gynecomastia will be reviewed here. An overview of gynecomastia in children and adolescents and the epidemiology, causes, and evaluation of gynecomastia in adults are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14310.html" rel="external">"Gynecomastia in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/7466.html" rel="external">"Epidemiology, pathophysiology, and causes of gynecomastia"</a> and  <a class="medical medical_review" href="/z/d/html/7476.html" rel="external">"Clinical features, diagnosis, and evaluation of gynecomastia in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>The management of gynecomastia depends upon its etiology, duration, severity, and the presence or absence of tenderness.</p><p class="bulletIndent1"><span class="glyph">●</span>A careful breast examination is the first step to distinguishing true gynecomastia (enlargement of the glandular tissue) from pseudogynecomastia (excessive adipose tissue)  (<a class="graphic graphic_figure graphicRef72334" href="/z/d/graphic/72334.html" rel="external">figure 1</a>). Additional details on the breast examination and evaluation of the patient with gynecomastia are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7476.html" rel="external">"Clinical features, diagnosis, and evaluation of gynecomastia in adults", section on 'Evaluation to determine cause'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pubertal gynecomastia (a benign, physiologic process) is common in adolescent boys, often developing between ages 10 and 12 years, with a peak prevalence of 65 percent between ages 13 and 14 years, followed by regression in approximately 80 percent within six months to two years. In up to 20 percent, pubertal gynecomastia persists into adulthood  (<a class="graphic graphic_figure graphicRef64368" href="/z/d/graphic/64368.html" rel="external">figure 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The simplest method to prevent or manage gynecomastia is to avoid or discontinue drugs that cause it  (<a class="graphic graphic_table graphicRef71421" href="/z/d/graphic/71421.html" rel="external">table 2</a>). (See <a class="local">'Stop offending drugs'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gynecomastia of recent onset (&lt;6 months) often regresses spontaneously, so observation alone is the initial step for many patients, especially those with pubertal gynecomastia or following the correction of the cause, such as discontinuation of a medication known to be associated with gynecomastia [<a href="#rid2">2</a>]. (See <a class="local">'Observation only'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential indications for early medical therapy include significant breast enlargement (&gt;4 cm in diameter in young men), pain, tenderness, and embarrassment that interfere with the patient's normal daily activities (see <a class="local">'Pharmacologic therapy'</a> below). Surgical intervention might be needed in patients with persistent gynecomastia, including those with pubertal gynecomastia that persists into late adolescence or early adulthood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gynecomastia is the most symptomatic (pain and tenderness) and treatable in its early stages (first six months). After approximately 12 months, fibrotic tissue eventually replaces glandular tissue and tenderness resolves. Pharmacologic therapy is unlikely to be beneficial once fibrous tissue is present. Surgery effectively removes excess breast tissue at any time, but it is delayed until the underlying cause of gynecomastia has been addressed (to avoid recurrence after surgery) [<a href="#rid3">3</a>]. (See <a class="local">'Pharmacologic therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe gynecomastia, with large pendulous breasts and skin redundancy, is unlikely to respond to pharmacologic therapy and nearly always requires surgery for an optimal cosmetic result. (See <a class="local">'Surgery'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The approach to unilateral gynecomastia is the same as for bilateral gynecomastia. It is especially important to distinguish unilateral gynecomastia from breast carcinoma and other lesions by physical examination, ultrasonography, and/or mammography. (See  <a class="medical medical_review" href="/z/d/html/7476.html" rel="external">"Clinical features, diagnosis, and evaluation of gynecomastia in adults"</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>The approach to management begins with the simplest and least invasive steps, including observation only, stopping causative medications, and treating underlying medical problems associated with gynecomastia. If gynecomastia does not resolve within three months with these measures and the patient has pain and tenderness, medical therapy is typically the next step. Surgical intervention should be considered in men whose gynecomastia does not regress spontaneously, is causing considerable discomfort or psychological distress, or is longstanding (greater than 12 months) and in which the fibrotic stage has been reached [<a href="#rid4">4,5</a>].</p><p>A major factor that should influence the initial approach to management is the duration of gynecomastia. Histologic studies show that the glandular changes in the breast are the same regardless of etiology and that the extent of glandular proliferation depends upon the intensity and duration of the stimulation (see  <a class="medical medical_review" href="/z/d/html/7476.html" rel="external">"Clinical features, diagnosis, and evaluation of gynecomastia in adults", section on 'Histology'</a>). Gynecomastia is the most symptomatic in the early stages (first six months), when ductal hyperplasia and periductal inflammation are present. During this time period, gynecomastia is also the most treatable with medications.</p><p>The goal in men with prostate cancer undergoing hormone therapy (androgen deprivation therapy or antiandrogen monotherapy) is to prevent the development of gynecomastia. The best options include <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> and radiation therapy. (See <a class="local">'Men with prostate cancer'</a> below.)</p><p class="headingAnchor" id="H215957494"><span class="h2">Stop offending drugs</span><span class="headingEndMark"> — </span>The first step in the management of new gynecomastia is to discontinue, if possible, any drugs that cause it, such as <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>  (<a class="graphic graphic_table graphicRef71421" href="/z/d/graphic/71421.html" rel="external">table 2</a>). If the drug is identified as the cause of gynecomastia during the early, proliferative, and often painful phase, stopping it may result in regression of glandular tissue (within one month of stopping the drug) [<a href="#rid1">1</a>]. On the other hand, if the gynecomastia has been present for more than one year, stopping the offending drug is unlikely to result in spontaneous regression of glandular tissue, because fibrosis is likely to be present.</p><p>If gynecomastia and breast tenderness does not resolve within three months after stopping the causative drug or if the causative medication cannot be discontinued, medical therapy can be considered.</p><p class="headingAnchor" id="H20245823"><span class="h2">Observation only</span><span class="headingEndMark"> — </span>Gynecomastia often regresses spontaneously, so observation alone is often the initial step (if there are no possible inciting drugs). This is only effective if the gynecomastia is in the early proliferative phase (eg, present for less than one year). Otherwise, fibrosis is likely to be present and glandular tissue will not regress spontaneously. We suggest observation without medical therapy after stopping offending medications and/or treating any underlying disorders. Patients with recent-onset gynecomastia should be seen at three-month intervals to determine if the gynecomastia is resolving spontaneously or if a medication trial should be initiated.</p><p>Pubertal gynecomastia (a benign, physiologic process) typically develops between ages 10 and 12 years, with a peak prevalence of 65 percent between ages 13 and 14 years, followed by regression in 80 percent within six months to two years. It may persist into adulthood in up to 20 percent of individuals  (<a class="graphic graphic_figure graphicRef64368" href="/z/d/graphic/64368.html" rel="external">figure 2</a>). Observation alone is a reasonable approach in most adolescent boys.</p><p>Regression of gynecomastia is also common in adults. In one report, regression of breast tissue occurred in 85 percent of adult men with gynecomastia due to various causes [<a href="#rid2">2</a>]. In contrast, in therapeutic trials, complete spontaneous regression in men receiving drug therapy or placebo is much less frequent. (See <a class="local">'Pharmacologic therapy'</a> below.)</p><p class="headingAnchor" id="H20245611"><span class="h2">Treat underlying condition</span><span class="headingEndMark"> — </span>In men with gynecomastia due to an underlying treatable disorder such as hypogonadism or hyperthyroidism, we suggest treatment of the underlying disorder first, followed by observation with a follow-up breast examination in three months to see if the gynecomastia is resolving.</p><p class="headingAnchor" id="H11"><span class="h2">Pharmacologic therapy</span><span class="headingEndMark"> — </span>Three classes of medications, selective estrogen receptor modulators (SERMs), aromatase inhibitors, and androgens (for men with hypogonadism), have been studied for the treatment of gynecomastia. For men with indications for medical therapy, we suggest <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>, unless they have hypogonadism, in which case we suggest testosterone therapy. Potential indications for early intervention with pharmacotherapy include pain, tenderness, and embarrassment that interfere with the patient's normal daily activities. Although they may not induce complete regression of gynecomastia, they may result in partial regression and relief of tenderness. None are approved for the treatment of gynecomastia.</p><p>Medical therapy may be effective in the early active phase of gynecomastia but not in the late fibrotic stage (after 12 months). Surgical intervention might be necessary in patients with persistent gynecomastia, including those with pubertal gynecomastia that persists into late adolescence or early adulthood.</p><p class="headingAnchor" id="H12"><span class="h3">Androgens</span><span class="headingEndMark"> — </span>Testosterone replacement in hypogonadal men often improves gynecomastia [<a href="#rid4">4,6,7</a>], but there is no rationale for its use in eugonadal men, in whom it may actually worsen the gynecomastia due to aromatization of the testosterone to estradiol. (See  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism"</a>.)</p><p>The nonaromatizable androgen dihydrotestosterone (available as a gel in some countries) has been reported to be effective for gynecomastia in uncontrolled studies [<a href="#rid8">8,9</a>], but there is insufficient information to recommend its use.</p><p class="headingAnchor" id="H13"><span class="h3">Selective estrogen receptor modulators (SERMs)</span><span class="headingEndMark"> — </span>For adolescent <strong>boys</strong> with severe breast enlargement that is confirmed to be glandular tissue and is causing substantial tenderness and/or embarrassment, we suggest a brief trial (three months) of a SERM. A systematic review of six studies of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> therapy suggests that tamoxifen is beneficial and well tolerated [<a href="#rid10">10</a>]. A retrospective chart review of tamoxifen and <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a> therapy reported that both drugs decreased glandular tissue, but neither resulted in complete resolution of the gynecomastia [<a href="#rid11">11</a>].</p><p>We currently use <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> (20 mg once daily or 10 mg twice daily) for three months because there is inadequate experience with <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a> in this population. Patients and parents/caregivers should be told that these drugs are not approved for this purpose.</p><p>For <strong>adults</strong> in whom no cause can be identified and the gynecomastia is tender and persists more than three months, we suggest a brief trial (three to six months) of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> for relief of symptoms. Although clinical trial data are limited, tamoxifen and <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a> appear to decrease breast volume in adults with gynecomastia. However, despite some positive reports, complete breast regression may not be achieved with this approach, and these drugs are not approved for the treatment of gynecomastia [<a href="#rid12">12</a>].</p><p><a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">Tamoxifen</a> therapy for up to three months has been reported to result in pain relief (for those with gynecomastia associated with pain and tenderness) and at least partial regression of glandular tissue in approximately 80 percent of men [<a href="#rid1">1,13-17</a>].</p><p>In a retrospective series, <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> appeared to be more effective than <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> therapy [<a href="#rid15">15</a>]. Adverse events in men taking tamoxifen are rare but include epigastric distress and one report of a posttraumatic deep venous thrombosis [<a href="#rid1">1,17</a>].</p><p>In summary, although SERMs may not result in complete regression of breast tissue, they may be effective for patients with painful gynecomastia. We suggest a three-month trial of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> for <strong>adolescents</strong> with severe breast enlargement that is confirmed to be glandular tissue and is causing substantial tenderness and/or embarrassment. We suggest a similar approach for <strong>men</strong> prior to considering surgery. We typically choose tamoxifen over other SERMs, such as <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a>, since it is the best studied of the SERMs and is reasonably well tolerated. We evaluate patients after three months to determine if the therapy is effective.</p><p class="headingAnchor" id="H14"><span class="h3">Aromatase inhibitors</span><span class="headingEndMark"> — </span>We do not suggest aromatase inhibitors for the prevention or treatment of gynecomastia. Aromatase inhibitors block estrogen biosynthesis and should theoretically be effective for gynecomastia by decreasing the estrogen-to-androgen ratio [<a href="#rid18">18</a>]. However, clinical trials to date have not demonstrated an important clinical benefit of these drugs for gynecomastia in either adolescents or men with prostate cancer. The reason for this is unknown. (See  <a class="medical medical_review" href="/z/d/html/7466.html" rel="external">"Epidemiology, pathophysiology, and causes of gynecomastia"</a> and <a class="local">'Men with prostate cancer'</a> below.)</p><p class="headingAnchor" id="H15"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Surgical therapy should be considered in men whose gynecomastia does not regress spontaneously, is causing considerable discomfort or psychological distress, or is longstanding (greater than 12 months) <strong>and</strong> the fibrotic stage has been reached [<a href="#rid5">5,19</a>]. There was a 19 percent increase in gynecomastia surgery between 2000 and 2019, with 24,123 male breast reduction surgeries being performed in 2019 [<a href="#rid20">20</a>]. (See <a class="local">'Pharmacologic therapy'</a> above.)</p><p>For adolescents, surgery is generally not recommended until adult testicular size is attained, as there may be regrowth of the breast tissue if the surgery is performed before puberty is completed.</p><p>The extent of surgery depends upon the severity of the breast enlargement and whether there is also excess adipose tissue present. Multiple classification schemes have been published to grade the degree of gynecomastia. Men with moderate (6 to 11 cm in diameter) to severe gynecomastia (&gt;11 cm) are unlikely to undergo spontaneous regression. Surgical outcomes are generally better for those with minimal or moderate breast enlargement without skin redundancy than those with severe enlargement with stretched, redundant skin [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H20245030"><span class="h3">Procedure</span><span class="headingEndMark"> — </span>Many patients are treated with a combination of direct surgical excision of the glandular tissue and liposuction of any coexisting adipose tissue through a periareolar incision [<a href="#rid5">5,19,21</a>].</p><p>More extensive cosmetic surgery, including skin excision, is required for patients with marked gynecomastia or who develop excessive sagging of the breast tissue, as occurs with weight loss [<a href="#rid19">19,22,23</a>]. A transverse ellipse of excessive skin, fat, and glandular tissue is excised, and the nipple-areola complex is removed as a full thickness graft and replaced in the appropriate anatomic position following removal of the redundant tissue [<a href="#rid22">22</a>]. Alternatively, the nipple-areola complex may remain attached to the surrounding dermis and blood supply and be rotated upward into its proper position after the excessive tissue is excised.</p><p class="headingAnchor" id="H20245036"><span class="h3">Outcome</span><span class="headingEndMark"> — </span>Potential complications of surgical therapy for gynecomastia include sloughing of tissue due to compromise of the blood supply, contour irregularity, hematoma or seroma formation, and numbness of the nipple-areolar area [<a href="#rid5">5,21-25</a>]. However, when surgery is performed by an experienced cosmetic surgeon, complication rates are low, as illustrated in a series of 107 men with gynecomastia treated in one center [<a href="#rid21">21</a>]. Only one patient had a postoperative complication (dehiscence of the surgical wound). All but 2 of the 107 patients were considered to have a satisfactory cosmetic result (excellent in 94 patients, good in 11).</p><p class="headingAnchor" id="H20245049"><span class="h3">Pathology</span><span class="headingEndMark"> — </span>The histopathologic findings from surgical breast specimens almost always show gynecomastia; breast cancer is extremely rare. In a report of 3719 surgical procedures performed for gynecomastia (5113 breast specimens), the most common pathology diagnosis was gynecomastia (94.1 percent), followed by pseudogynecomastia (5.3 percent) [<a href="#rid26">26</a>]. The overall prevalence of invasive breast carcinoma, ductal carcinoma in situ, and atypical ductal hyperplasia was 0.11, 0.18, and 0.4 percent (4, 7, and 18 cases), respectively.</p><p class="headingAnchor" id="H16"><span class="h2">Men with prostate cancer</span><span class="headingEndMark"> — </span>Gynecomastia is common in men with prostate cancer undergoing androgen deprivation. The prevalence of gynecomastia is approximately 15 percent in men treated with total androgen blockade (gonadotropin-releasing hormone [GnRH] agonists combined with an antiandrogen) [<a href="#rid27">27</a>]. However, the prevalence is as high as 75 percent when antiandrogen monotherapy is used [<a href="#rid28">28-30</a>]. Much higher doses of antiandrogens are used for monotherapy (eg, <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">bicalutamide</a> 150 versus 50 mg if combined with a GnRH agonist). (See  <a class="medical medical_review" href="/z/d/html/6941.html" rel="external">"Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer"</a>.)</p><p>Prevention of gynecomastia is the goal of therapy, although effective treatment strategies are available for men who did not receive prophylaxis. Strategies that have been used for prevention include pharmacologic therapy (SERMs [<a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>]) or radiotherapy [<a href="#rid27">27,31,32</a>]. Aromatase inhibitors have been studied but do not appear to be effective.</p><p class="headingAnchor" id="H17"><span class="h3">Tamoxifen</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">Tamoxifen</a> is effective for preventing antiandrogen-associated gynecomastia. In three trials of men with prostate cancer receiving high doses (150 mg/day) of the antiandrogen <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">bicalutamide</a> alone or with tamoxifen (10 to 20 mg/day) [<a href="#rid32">32-34</a>], gynecomastia occurred in 86 of 124 patients (69 percent) treated with bicalutamide alone compared with 11 of 122 patients (9 percent) treated with bicalutamide plus tamoxifen. Tamoxifen must be continued for the duration of antiandrogen therapy as its effect does not persist after it is discontinued [<a href="#rid35">35</a>].</p><p><a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">Tamoxifen</a> is more effective given daily than weekly [<a href="#rid36">36</a>], and prophylaxis with tamoxifen 10 mg/day started with <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">bicalutamide</a> is more effective than 20 mg/day started one month after gynecomastia first develops [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H18"><span class="h3">Anastrozole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">Anastrozole</a> reduces the incidence of antiandrogen-associated gynecomastia but is less effective than <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>. This was illustrated in a trial of 88 men with prostate cancer who were randomly assigned to <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">bicalutamide</a> alone or to bicalutamide plus either anastrozole (1 mg/day) or tamoxifen (20 mg/day) for 48 weeks [<a href="#rid34">34</a>]. Gynecomastia developed in 73, 51, and 10 percent of men receiving bicalutamide alone, bicalutamide with anastrozole, or bicalutamide with tamoxifen, respectively.</p><p class="headingAnchor" id="H19"><span class="h3">Radiotherapy</span><span class="headingEndMark"> — </span>Prophylactic radiotherapy prevents antiandrogen-associated gynecomastia in some, but not all, men [<a href="#rid31">31</a>]. In four trials of prophylactic, low-dose bilateral breast radiotherapy (10 to 15 Gy in either one fraction or over three days), gynecomastia occurred in 155 of 215 patients (72 percent) treated with <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">bicalutamide</a> alone compared with 105 of 322 patients (33 percent) treated with bicalutamide plus prophylactic radiotherapy [<a href="#rid32">32,33,38,39</a>].</p><p>Treatment of established gynecomastia with higher radiation doses (eg, 20 Gy in five fractions) may improve pain and tenderness but is less effective at reducing the volume of tissue [<a href="#rid40">40</a>].</p><p>A Norwegian registry-based study did not demonstrate an increased risk of breast cancer in patients who received prophylactic breast radiotherapy [<a href="#rid41">41</a>]. However, the study had a relatively short follow-up period (median = 4 years), and the study was too small to detect changes in incidence in breast cancer, a disease that is rare in men.</p><p class="headingAnchor" id="H20"><span class="h3">Tamoxifen versus radiotherapy</span><span class="headingEndMark"> — </span>For men at high risk for venous thromboembolism, we suggest radiotherapy rather than <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Tamoxifen'</a>.)</p><p>Data on the efficacy of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> versus radiotherapy for preventing gynecomastia in men receiving high-dose <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">bicalutamide</a> monotherapy (150 mg/day) after radical prostatectomy are conflicting [<a href="#rid32">32,33,43</a>]. In one trial of 102 men, gynecomastia developed in 68, 8, and 34 percent of patients receiving bicalutamide alone, bicalutamide combined with tamoxifen (10 mg/day), or prophylactic radiotherapy, respectively, suggesting that tamoxifen is superior to radiotherapy [<a href="#rid32">32</a>].</p><p>Results of two meta-analyses suggest that while <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> 20 mg/day is the most effective agent for <strong>preventing</strong> gynecomastia, it is also associated with more side effects than radiotherapy or aromatase inhibitors [<a href="#rid43">43,44</a>]. Weekly tamoxifen (as opposed to daily) and aromatase inhibitors were ineffective. One meta-analysis of nine trials including 1573 men suggested that radiotherapy was more effective than tamoxifen for <strong>treatment</strong> of bicalutamide-induced gynecomastia [<a href="#rid44">44</a>].</p><p>Based upon these meta-analyses and the known risks of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> and radiotherapy, we recommend tamoxifen over radiotherapy for prevention of gynecomastia in patients being treated with high-dose <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">bicalutamide</a> monotherapy.</p><p class="headingAnchor" id="H21"><span class="h3">Surgical intervention</span><span class="headingEndMark"> — </span>Surgical prophylaxis of gynecomastia has been described, but surgery (subcutaneous mastectomy, liposuction) is most often considered for established disease [<a href="#rid29">29,45</a>]. (See <a class="local">'Surgery'</a> above.)</p><p class="headingAnchor" id="H10402820"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16107.html" rel="external">"Patient education: Gynecomastia (male breast development) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2186.html" rel="external">"Patient education: Gynecomastia (breast enlargement in males) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>The management of gynecomastia depends upon a number of factors, including its etiology, duration, severity, and the presence or absence of tenderness. When gynecomastia persists beyond 12 months, the breast glandular tissue has typically become fibrotic and medical therapy is unlikely to be effective. (See <a class="local">'Pharmacologic therapy'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Pubertal gynecomastia (a benign, physiologic process) typically develops between ages 10 and 12 years, with a peak prevalence of 65 percent between ages 13 and 14 years, followed by regression in approximately 80 percent within six months to two years. Its persistence into adulthood is uncommon  (<a class="graphic graphic_figure graphicRef64368" href="/z/d/graphic/64368.html" rel="external">figure 2</a>). Thus, observation without treatment is a reasonable approach in most adolescent boys.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most men with gynecomastia, we suggest initial observation without treatment with follow-up re-evaluation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), especially in men with drug-induced gynecomastia or men with an underlying treatable disorder such as hypogonadism or hyperthyroidism, once the drug has been stopped and/or the underlying disorder has been treated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For adolescent <strong>boys</strong> with severe breast enlargement that is confirmed to be glandular tissue and is causing substantial tenderness and/or embarrassment, we suggest a brief trial (three months) of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> (10 mg twice daily) for relief of tenderness (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We do not use aromatase inhibitors, as they do not appear to be effective.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For men in whom no cause can be identified and the gynecomastia is tender and persists more than three months, we suggest a brief trial (three to six months) of a selective estrogen receptor modulator (SERM) for relief of tenderness (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We currently use <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> (10 mg twice daily) because there is inadequate experience with <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a>. Patients should be told that SERMs are not approved for this purpose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In men with persistent gynecomastia (&gt;1 to 2 years) that the patient finds troubling psychologically, we suggest surgery because the breast tissue has probably become fibrotic and unresponsive to drug therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For prevention of gynecomastia in men with advanced prostate cancer undergoing high-dose antiandrogen monotherapy, we suggest <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> therapy to reduce the risk of developing gynecomastia (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, for men with known risk factors for venous thromboembolism, we suggest radiotherapy rather than tamoxifen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest not using aromatase inhibitors for prevention, because they do not appear to be effective in this setting.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For men who have already developed gynecomastia on antiandrogen therapy, we use <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> therapy (if it is of recent onset and likely to be in its proliferative phase).</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357:1229.</a></li><li><a class="nounderline abstract_t">TREVES N. Gynecomastia; the origins of mammary swelling in the male: an analysis of 406 patients with breast hypertrophy, 525 with testicular tumors, and 13 with adrenal neoplasms. Cancer 1958; 11:1083.</a></li><li><a class="nounderline abstract_t">Johnson RE, Murad MH. Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin Proc 2009; 84:1010.</a></li><li><a class="nounderline abstract_t">Gruntmanis U, Braunstein GD. Treatment of gynecomastia. Curr Opin Investig Drugs 2001; 2:643.</a></li><li><a class="nounderline abstract_t">Gikas P, Mokbel K. Management of gynaecomastia: an update. Int J Clin Pract 2007; 61:1209.</a></li><li><a class="nounderline abstract_t">Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999; 84:3469.</a></li><li><a class="nounderline abstract_t">Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. The Copenhagen Study Group for Liver Diseases. Hepatology 1986; 6:807.</a></li><li><a class="nounderline abstract_t">Kuhn JM, Roca R, Laudat MH, et al. Studies on the treatment of idiopathic gynaecomastia with percutaneous dihydrotestosterone. Clin Endocrinol (Oxf) 1983; 19:513.</a></li><li><a class="nounderline abstract_t">Eberle AJ, Sparrow JT, Keenan BS. Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate. J Pediatr 1986; 109:144.</a></li><li><a class="nounderline abstract_t">Lapid O, van Wingerden JJ, Perlemuter L. Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review. J Pediatr Endocrinol Metab 2013; 26:803.</a></li><li><a class="nounderline abstract_t">Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr 2004; 145:71.</a></li><li><a class="nounderline abstract_t">Mannu GS, Sudul M, Bettencourt-Silva JH, et al. Role of tamoxifen in idiopathic gynecomastia: A 10-year prospective cohort study. Breast J 2018; 24:1043.</a></li><li><a class="nounderline abstract_t">Parker LN, Gray DR, Lai MK, Levin ER. Treatment of gynecomastia with tamoxifen: a double-blind crossover study. Metabolism 1986; 35:705.</a></li><li><a class="nounderline abstract_t">McDermott MT, Hofeldt FD, Kidd GS. Tamoxifen therapy for painful idiopathic gynecomastia. South Med J 1990; 83:1283.</a></li><li><a class="nounderline abstract_t">Ting AC, Chow LW, Leung YF. Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia. Am Surg 2000; 66:38.</a></li><li><a class="nounderline abstract_t">Hanavadi S, Banerjee D, Monypenny IJ, Mansel RE. The role of tamoxifen in the management of gynaecomastia. Breast 2006; 15:276.</a></li><li><a class="nounderline abstract_t">Wibowo E, Pollock PA, Hollis N, Wassersug RJ. Tamoxifen in men: a review of adverse events. Andrology 2016; 4:776.</a></li><li><a class="nounderline abstract_t">Braunstein GD. Aromatase and gynecomastia. Endocr Relat Cancer 1999; 6:315.</a></li><li><a class="nounderline abstract_t">Cordova A, Moschella F. Algorithm for clinical evaluation and surgical treatment of gynaecomastia. J Plast Reconstr Aesthet Surg 2008; 61:41.</a></li><li class="breakAll">https://www.plasticsurgery.org/documents/News/Statistics/2019/plastic-surgery-statistics-full-report-2019.pdf (Accessed on April 19, 2021).</li><li><a class="nounderline abstract_t">Gioffrè Florio MA, Alfio AR, Famà F, et al. [Evaluation of complications and long-term results after surgery for gynaecomastia]. Chir Ital 2004; 56:113.</a></li><li><a class="nounderline abstract_t">El-Khatib HA. A single stage liposuction and dermopexy for grade 3b and grade 4 pseudogynecomastia after massive weight loss: an observational study. Int J Surg 2007; 5:155.</a></li><li><a class="nounderline abstract_t">Tashkandi M, Al-Qattan MM, Hassanain JM, et al. The surgical management of high-grade gynecomastia. Ann Plast Surg 2004; 53:17.</a></li><li><a class="nounderline abstract_t">Steele SR, Martin MJ, Place RJ. Gynecomastia: complications of the subcutaneous mastectomy. Am Surg 2002; 68:210.</a></li><li><a class="nounderline abstract_t">Mentz HA, Ruiz-Razura A, Newall G, et al. Correction of gynecomastia through a single puncture incision. Aesthetic Plast Surg 2007; 31:244.</a></li><li><a class="nounderline abstract_t">Lapid O, Jolink F, Meijer SL. Pathological findings in gynecomastia: analysis of 5113 breasts. Ann Plast Surg 2015; 74:163.</a></li><li><a class="nounderline abstract_t">Fagerlund A, Cormio L, Palangi L, et al. Gynecomastia in Patients with Prostate Cancer: A Systematic Review. PLoS One 2015; 10:e0136094.</a></li><li><a class="nounderline abstract_t">Chang A, Yeap B, Davis T, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14:2250.</a></li><li><a class="nounderline abstract_t">Dobs A, Darkes MJ. Incidence and management of gynecomastia in men treated for prostate cancer. J Urol 2005; 174:1737.</a></li><li><a class="nounderline abstract_t">Schröder FH, Collette L, de Reijke TM, Whelan P. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Br J Cancer 2000; 82:283.</a></li><li><a class="nounderline abstract_t">Dicker AP. The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol 2003; 4:30.</a></li><li><a class="nounderline abstract_t">Di Lorenzo G, Perdonà S, De Placido S, et al. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J Urol 2005; 174:2197.</a></li><li><a class="nounderline abstract_t">Perdonà S, Autorino R, De Placido S, et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 2005; 6:295.</a></li><li><a class="nounderline abstract_t">Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005; 23:808.</a></li><li><a class="nounderline abstract_t">Fradet Y, Egerdie B, Andersen M, et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol 2007; 52:106.</a></li><li><a class="nounderline abstract_t">Bedognetti D, Rubagotti A, Conti G, et al. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur Urol 2010; 57:238.</a></li><li><a class="nounderline abstract_t">Serretta V, Altieri V, Morgia G, et al. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. Clin Genitourin Cancer 2012; 10:174.</a></li><li><a class="nounderline abstract_t">Tyrrell CJ, Payne H, Tammela TL, et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 2004; 60:476.</a></li><li><a class="nounderline abstract_t">Widmark A, Fosså SD, Lundmo P, et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 2003; 61:145.</a></li><li><a class="nounderline abstract_t">Chou JL, Easley JD, Feldmeier JJ, et al. Effective radiotherapy in palliating mammalgia associated with gynecomastia after DES therapy. Int J Radiat Oncol Biol Phys 1988; 15:749.</a></li><li><a class="nounderline abstract_t">Aksnessæther BY, Solberg A, Klepp OH, et al. Does Prophylactic Radiation Therapy to Avoid Gynecomastia in Patients With Prostate Cancer Increase the Risk of Breast Cancer? Int J Radiat Oncol Biol Phys 2018; 101:211.</a></li><li><a class="nounderline abstract_t">Ghadjar P, Aebersold DM, Albrecht C, et al. Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer. Strahlenther Onkol 2020; 196:589.</a></li><li><a class="nounderline abstract_t">Viani GA, Bernardes da Silva LG, Stefano EJ. Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy? Int J Radiat Oncol Biol Phys 2012; 83:e519.</a></li><li><a class="nounderline abstract_t">Tunio MA, Al-Asiri M, Al-Amro A, et al. Optimal prophylactic and definitive therapy for bicalutamide-induced gynecomastia: results of a meta-analysis. Curr Oncol 2012; 19:e280.</a></li><li><a class="nounderline abstract_t">Yang Y, Mu D, Xu B, et al. Endoscopic subcutaneous mastectomy plus liposuction via a single axillary incision for gynecomastia in Asian patients: A report of 45 cases. Surgery 2021; 170:39.</a></li></ol></div><div id="topicVersionRevision">Topic 7467 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17881754" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice. Gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13608407" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Gynecomastia; the origins of mammary swelling in the male: an analysis of 406 patients with breast hypertrophy, 525 with testicular tumors, and 13 with adrenal neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19880691" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Gynecomastia: pathophysiology, evaluation, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11569940" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17362482" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of gynaecomastia: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522982" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2875927" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. The Copenhagen Study Group for Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6354523" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Studies on the treatment of idiopathic gynaecomastia with percutaneous dihydrotestosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3088241" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23729603" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15238910" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30079473" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Role of tamoxifen in idiopathic gynecomastia: A 10-year prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3526085" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of gynecomastia with tamoxifen: a double-blind crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2237557" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tamoxifen therapy for painful idiopathic gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10651345" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15998589" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The role of tamoxifen in the management of gynaecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27152880" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tamoxifen in men: a review of adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10731125" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Aromatase and gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17983883" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Algorithm for clinical evaluation and surgical treatment of gynaecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17983883" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Algorithm for clinical evaluation and surgical treatment of gynaecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15038656" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : [Evaluation of complications and long-term results after surgery for gynaecomastia].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17509496" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A single stage liposuction and dermopexy for grade 3b and grade 4 pseudogynecomastia after massive weight loss: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15211192" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The surgical management of high-grade gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11842972" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Gynecomastia: complications of the subcutaneous mastectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17380361" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Correction of gynecomastia through a single puncture incision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23788148" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pathological findings in gynecomastia: analysis of 5113 breasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26308532" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Gynecomastia in Patients with Prostate Cancer: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8708714" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16217274" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Incidence and management of gynecomastia in men treated for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10646878" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517537" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16280763" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863377" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15681525" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17270340" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19481335" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22502790" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15380582" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12559286" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2458332" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effective radiotherapy in palliating mammalgia associated with gynecomastia after DES therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29534900" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Does Prophylactic Radiation Therapy to Avoid Gynecomastia in Patients With Prostate Cancer Increase the Risk of Breast Cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32166452" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22704706" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22876157" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Optimal prophylactic and definitive therapy for bicalutamide-induced gynecomastia: results of a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33715850" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Endoscopic subcutaneous mastectomy plus liposuction via a single axillary incision for gynecomastia in Asian patients: A report of 45 cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
